Published in Infect Immun on October 01, 1999
The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev (2008) 5.32
Anni 2.0: a multipurpose text-mining tool for the life sciences. Genome Biol (2008) 2.04
Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major. Infect Immun (2004) 0.92
Alteration of Fas and Fas ligand expression during human visceral leishmaniasis. Clin Exp Immunol (2002) 0.88
Partners in crime: co-infections in the developing world. Clin Exp Immunol (2000) 0.82
Magnitude of visceral leishmaniasis and poor treatment outcome among HIV patients: meta-analysis and systematic review. HIV AIDS (Auckl) (2016) 0.80
CD4+ CCR5+ and CD4+ CCR3+ lymphocyte subset and monocyte apoptosis in patients with acute visceral leishmaniasis. Immunology (2004) 0.79
Decreased memory T-cell response and function in human immunodeficiency virus-infected patients with tegumentary leishmaniasis. Mem Inst Oswaldo Cruz (2013) 0.76
Prevalence of Human Immunodeficiency Virus and associated factors among Visceral Leishmaniasis infected patients in Northwest Ethiopia: a facility based cross-sectional study. BMC Infect Dis (2017) 0.75
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J (1990) 9.34
Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B. Nature (1989) 5.76
Host factors and the pathogenesis of HIV-induced disease. Nature (1996) 4.96
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med (1991) 4.43
Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev (1997) 4.09
Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol (1990) 3.56
The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today (1994) 3.01
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol (1996) 2.86
Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today (1995) 2.84
Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat. J Clin Invest (1995) 1.68
Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med (1995) 1.46
Plasmodium falciparum antigen-induced human immunodeficiency virus type 1 replication is mediated through induction of tumor necrosis factor-alpha. J Infect Dis (1998) 1.42
Leishmania-HIV interaction: immunopathogenic mechanisms. Parasitol Today (1999) 1.31
Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J Infect Dis (1993) 1.23
Natural and acquired resistance to Leishmania: cellular activation by Leishmania aethiopica of mononuclear cells from unexposed individuals is through the stimulation of natural killer (NK) cells. Clin Exp Immunol (1993) 1.07
Cytokines in the differentiation of Th1/Th2 CD4+ subsets in leishmaniasis. J Cell Biochem (1993) 1.03
Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retroviruses (1997) 0.99
Activation of human immunodeficiency virus type 1 in monocytoid cells by the protozoan parasite Leishmania donovani. J Virol (1995) 0.98
Cytokine activation of human macrophages infected with HIV-1 to inhibit intracellular protozoa. J Acquir Immune Defic Syndr (1992) 0.96
Increased in vitro tetanus-induced production of HIV type 1 following in vivo immunization of HIV type 1-infected individuals with tetanus toxoid. AIDS Res Hum Retroviruses (1997) 0.94
The lipophosphoglycan of Leishmania donovani up-regulates HIV-1 transcription in T cells through the nuclear factor-kappaB elements. J Immunol (1998) 0.92
Live and killed human immunodeficiency virus type-1 increases the intracellular growth of Leishmania donovani in monocyte-derived cells. Scand J Infect Dis (1998) 0.90
HIV-1 inhibits Leishmania-induced cell proliferation but not production of interleukin-6 and tumour necrosis factor alpha. Scand J Immunol (1994) 0.82
Thalidomide inhibits lipoarabinomannan-induced upregulation of human immunodeficiency virus expression. Antimicrob Agents Chemother (1995) 0.79
A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet (1998) 3.76
Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis (1999) 3.61
Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro. Nature (1977) 2.58
Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guérin (BCG) vaccination. Clin Exp Immunol (2001) 2.43
Regulation of antibody synthesis against Escherichia coli endotoxin. I. Suppressive effect of endogenously produced and passively transferred antibodies. J Immunol (1968) 2.18
Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein-Barr virus-induced B-cell lines. Nature (1981) 2.10
A new approach to the study of human B lymphocyte function using an indirect plaque assay and a direct B cell activator. Immunol Rev (1979) 1.91
Persistence of immunogenicity of two complex antigens retained in vivo. Immunology (1968) 1.87
Computerization of undergraduate medical curriculum content. Med Educ (1984) 1.80
When allogeneic mouse spleen cells are mixed in vitro the T-cells secrete a product which guides the maturation of B-cells. Scand J Immunol (1972) 1.73
Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet (1999) 1.69
Thymus-dependent and thymus-independent effector functions of mouse lymphoid cells. Comparison of cytotoxicity and primary antibody formation in vitro. Cell Immunol (1973) 1.55
A live human B-cell activator operating in isolation of other cellular influences. Scand J Immunol (1979) 1.54
Cyclosporin A--usefulness, risks and mechanism of action. Immunol Rev (1982) 1.50
Regulation of antibody synthesis against Escherichia coli endotoxin. IV. Induction of paralysis in vitro by treating normal lymphoid cells with antigen. J Exp Med (1969) 1.50
No evidence for decreased lymphocyte reactivity in Crohn's disease. Gastroenterology (1974) 1.49
Characteristics of Epstein-Barr virus activation of human B lymphocytes. J Exp Med (1981) 1.43
Pokeweed mitogen induced differentiation of human B cells: evaluation by a protein A haemolytic plaque assay. Immunology (1979) 1.39
T-cell recognition of Mycobacterium tuberculosis culture filtrate fractions in tuberculosis patients and their household contacts. Infect Immun (1999) 1.38
Intracellular metabolism of 3'-azidothymidine in isolated human peripheral blood mononuclear cells. AIDS Res Hum Retroviruses (1991) 1.37
Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). Hum Mol Genet (1999) 1.31
Leishmania-HIV interaction: immunopathogenic mechanisms. Parasitol Today (1999) 1.31
A postgenomic approach to identification of Mycobacterium leprae-specific peptides as T-cell reagents. Infect Immun (2000) 1.24
Immunogenicity of human serum albumin: decay in the normal mouse. Immunology (1968) 1.23
Antibody patterns in different human sera against intracellular and membrane-antigen complexes associated with Epstein-Barr virus. J Natl Cancer Inst (1970) 1.23
Regulation of antibody synthesis against Escherichia coli endotoxin. II. Specificity, dose requirements and duration of paralysis induced in adult mice. Immunology (1969) 1.22
Genetic variability within the species Leishmania aethiopica does not correlate with clinical variations of cutaneous leishmaniasis. Mol Biochem Parasitol (2000) 1.21
Antigenic competition in vitro between heterologous erythrocytes. Eur J Immunol (1972) 1.20
Indications of the protective role of natural killer cells in human cutaneous leishmaniasis in an area of endemicity. Infect Immun (1998) 1.20
Circulating TNF-alpha, TGF-beta, and IL-10 in tuberculosis patients and healthy contacts. Scand J Immunol (2001) 1.20
Dissociation between delayed-type hypersensitivity and resistance to pathogenic mycobacteria demonstrated by T-cell clones. Infect Immun (1987) 1.20
Spontaneous production of interferon-gamma in adult and newborn humans. J Immunol (1984) 1.20
Low dose chronic Schistosoma mansoni infection increases susceptibility to Mycobacterium bovis BCG infection in mice. Clin Exp Immunol (2005) 1.18
Studies on epidemiological salmonellosis by fluorescent antibody technique. Acta Pathol Microbiol Scand (1966) 1.17
PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg (2005) 1.14
Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. Neurology (2001) 1.13
Experimental amyloidosis: the inducer is a polyclonal B-cell activator to which susceptibility is under genetic control. J Exp Med (1975) 1.07
Local production of nitric oxide in patients with tuberculosis. Int J Tuberc Lung Dis (2004) 1.06
HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS (1999) 1.06
Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study. J Infect Dis (1986) 1.06
Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection (1987) 1.05
Decrease in thymidylate kinase activity in peripheral blood mononuclear cells from HIV-infected individuals. Biochem Pharmacol (1998) 1.05
Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. Clin Exp Immunol (2003) 1.05
Immune responses to fractionated cytomegalovirus (CMV) antigens after HIV infection. Loss of cellular and humoral reactivity to antigens recognized by HIV-, CMV+ individuals. Clin Exp Immunol (1990) 1.05
Brugia pahangi: depressed mitogen reactivity in filarial infections in the jird, Meriones unguiculatus. Exp Parasitol (1976) 1.03
Differential recognition of Leishmania aethiopica antigens by lymphocytes from patients with local and diffuse cutaneous leishmaniasis. Evidence for antigen-induced immune suppression. J Immunol (1988) 1.03
Polymorphisms in Toll-like receptor 4 (TLR4) are associated with protection against leprosy. Eur J Clin Microbiol Infect Dis (2009) 1.03
Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis. Eur Respir J (2003) 1.03
Responsiveness in diffuse versus local cutaneous leishmaniasis is due to parasite differences. Scand J Immunol (1987) 1.02
A Leishmania homologue of receptors for activated C-kinase (LACK) induces both interferon-gamma and interleukin-10 in natural killer cells of healthy blood donors. J Infect Dis (2000) 1.02
Helminthes could influence the outcome of vaccines against TB in the tropics. Parasite Immunol (2006) 1.02
Frequencies of the separate human B cell subsets activatable to Ig secretion by Epstein-Barr virus and pokeweed mitogen. J Exp Med (1983) 1.01
Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism. AIDS Res Hum Retroviruses (1995) 1.01
Growth-retarding mechanisms against lymphatic tumours. Search in mice and men. Transplant Rev (1971) 1.00
Comparison of parasitological and immunological methods in the diagnosis of leishmaniasis in Ethiopia. Trans R Soc Trop Med Hyg (1992) 0.98
Heterogeneity of the effector cells in the cytotoxic reaction against allogeneic lymphoma cells. J Exp Med (1973) 0.98
Effects of a food supplement rich in arginine in patients with smear positive pulmonary tuberculosis--a randomised trial. Tuberculosis (Edinb) (2011) 0.97
Evidence for the ontogenic precedence of suppressor T cell functions in the human neonate. Eur J Immunol (1983) 0.97
Secretion of gamma-interferon at the cellular level. Induction by Epstein-Barr virus. Scand J Immunol (1984) 0.97
Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for interleukin-10 while those from localized leishmaniasis patients induce interferon-gamma. J Infect Dis (1997) 0.97
Regulation of antibody synthesis against Escherichia coli endotoxin. 3. Induction of immunological paralysis in non-immune and pre-immunized mice. Immunology (1969) 0.97
Monocyte function in infectious mononucleosis: evidence for a reversible cellular defect. J Infect Dis (1976) 0.96
HIV-1 alters T helper cytokines, interleukin-12 and interleukin-18 responses to the protozoan parasite Leishmania donovani. AIDS (2000) 0.94
Leishmania surface protein gp63 binds directly to human natural killer cells and inhibits proliferation. Clin Exp Immunol (2008) 0.93
Cellular mechanisms of restricted immunoglobulin formation in the human neonate. Eur J Immunol (1980) 0.93
Persistent productive HIV infection in EBV-transformed B lymphocytes. J Med Virol (1989) 0.93
Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection (1987) 0.93
Emerging Leishmania/HIV co-infection in Africa. Med Microbiol Immunol (2001) 0.92
Chest physiotherapy in primary pneumonia. Br Med J (Clin Res Ed) (1985) 0.90
Serum antibody specificities to Leishmania aethiopica antigens in patients with localized and diffuse cutaneous leishmaniasis. Parasite Immunol (1990) 0.90
The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas. Infection (1985) 0.90
Raised levels of tumour necrosis factor-alpha and neopterin, but not interferon-alpha, in serum of HIV-1-infected patients from Ethiopia. Clin Exp Immunol (1993) 0.90
The value of a direct agglutination test in the diagnosis of cutaneous and visceral leishmaniasis in Ethiopia. Trans R Soc Trop Med Hyg (1991) 0.90
Live and killed human immunodeficiency virus type-1 increases the intracellular growth of Leishmania donovani in monocyte-derived cells. Scand J Infect Dis (1998) 0.90
The interactive seminar: an educational approach for voluntary HIV testing in a drug dependence treatment unit. J Prof Nurs (1995) 0.90
Alteration of Fas and Fas ligand expression during human visceral leishmaniasis. Clin Exp Immunol (2002) 0.88
Differential induction of cellular responses by live and dead Leishmania promastigotes in healthy donors. Clin Exp Immunol (2001) 0.87
Expression of inducible nitric oxide synthase and nitrotyrosine in borderline leprosy lesions. Br J Dermatol (2001) 0.86
Polyclonal human T lymphocyte activation results in the secondary functional activation of the human B lymphocyte. Clin Exp Immunol (1981) 0.86
The immunological hazard of Cushing's syndrome. Br Med J (1975) 0.86
The nosocomial component of medical care. A prospective study on the amount, spectrum and costs of medical disturbances in a department of infectious diseases. Scand J Infect Dis Suppl (1982) 0.85
Unmasking and functional characterization of T-cell-replacing factors obtained from supernatants of allogeneic spleen cell mixtures. Scand J Immunol (1974) 0.85
Sequence analysis of selected regions of the env (V3 loop and gp41) and gag (p7) reading frames of Ethiopian human immunodeficiency virus type 1 strains. Arch Virol (1993) 0.85
Prevalence of HIV-1 infection and symptomatology of AIDS in severely malnourished children in Dar Es Salaam, Tanzania. J Acquir Immune Defic Syndr (1991) 0.85
Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis. Clin Exp Immunol (2001) 0.85
HIV-1 in Ethiopia: phylogenetic divergence from other HIV-1 strains. Virus Genes (1991) 0.84
Skin rash for 15 years. Lancet (1998) 0.84
Differences in PCR reactivity between HIV proviruses from individuals in Ethiopia and Sweden. J Acquir Immune Defic Syndr (1990) 0.84
Possible presence of DNA in intercellular bridges. Exp Cell Res (1967) 0.84